Loading stock data…
Compass (COMP)
$10.75-0.37 (-3.33%)
Market ClosedLast close Sep 8
Compass, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Compass, Inc. in the Real Estate sector is trading at $10.75 with a market capitalization of $6.9B. Wall Street consensus targets $15.42 (12 analysts), implying a +43.4% move over the next 12 months. The stock is currently 23% below its 52-week high of $13.96, remaining 6.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +43.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $2.06B↑ | $1.85B↑ | $1.70B↓ | $2.70B↓ | $4.31B |
| Gross Profit | $374.00M↑ | $342.60M↑ | $315.30M↓ | $696.00M↓ | $1.05B |
| Operating Income | $42.00M↑ | $2.60M↑ | -$28.40M↑ | -$162.00M↓ | $160.00M |
| Net Income | $39.00M↑ | -$4.60M↑ | -$42.60M↓ | $22.00M↓ | $92.00M |
Peer Comparison
Fundamentals
Compass, Inc. provides an end-to-end technology platform for residential real estate in the United States. The company offers the Compass Platform, a technology platform that provides an integrated suite of cloud-based software for customer relations...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.50%
Volume
Today's trading volume
9.57M
Recent News
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.
Q2 Rundown: Compass (NYSE:COMP) Vs Other Consumer Discretionary - Real Estate Services Stocks
Looking back on consumer discretionary - real estate services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Compass (NYSE:COMP) and its peers.
3 Reasons Growth Investors Will Love Compass (CMP)
Compass (CMP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.
Why Compass (COMP) Dropped And What Investors Are Watching
Recent commentary on Compass (COMP) has focused on slower sales growth, expense pressures, and negative operating margins. These factors together are shaping a cautious tone around the stock and its near term financial flexibility. See our latest analysis for Compass. At a latest share price of US$11.92, Compass has seen the 1 day share price return fall 6.88% and the 7 day share price return fall 10.71%. The 90 day share price return of 41.90% and 1 year total shareholder return of 40.40%...